Trial Profile
Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Rintatolimod (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DURIPANC
- 14 Feb 2024 According to an AIM ImmunoTech media release, fist patient has been dosed at Erasmus Medical Center in Netherlands.
- 22 Jan 2024 According to AIM ImmunoTech media release, the company expect to complete the Phase 1b portion of the study within six months.
- 22 Jan 2024 According to AIM ImmunoTech media release, the first subject has been enrolled at Erasmus Medical Center.